Evidence map›Paper›PMID 42682929›Full record

ReviewTherapeutic advances in psychopharmacology2026

Informing the patient of the placebo option: an ethical necessity likely to reduce inappropriate psychotropic prescriptions?

Fabrice Berna, Guillaume Durand, Rémy Boussageon, Julien Nizard, François Paille, Laurence Verneuil

Abstract readReview
In one paragraph

Review in Therapeutic advances in psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fabrice BernaUniversity of Strasbourg, University Hospitals of Strasbourg, Inserm U1329, 1 place de l'Hôpital, Strasbourg 67091, France.ORCID https://orcid.org/0000-0002-6118-0629
Guillaume DurandCentre Atlantique de PHIlosophie, UR 7463, Nantes Université, Nantes, France.ORCID https://orcid.org/0000-0002-6625-6223
Rémy BoussageonUniversity of Lyon 1, CNRS UMR 5558, LBBE, EMET, Lyon, France.ORCID https://orcid.org/0000-0002-8918-3186
Julien NizardUniversity of Nantes, CHU de Nantes, Service Douleur Soins de Support, Éthique clinique et Médecine intégrative, Nantes, France.ORCID https://orcid.org/0000-0003-1907-8628
François PailleUniversity of Lorraine, Nancy, France.
Laurence VerneuilInserm U1153, Statistic and Epidemiologic Research Center, Université Paris Cité, Paris, France.ORCID https://orcid.org/0000-0002-9843-9999

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing interest in deprescribing drugs highlights the importance of re-evaluating prescriptions, but also of limiting inappropriate prescribing. This paper reflects on the ethical use of a placebo as a way of limiting inappropriate prescribing. We focus on psychotropic drugs, but our reasoning may also concern other medical conditions. We analyze the conditions in which placebos are usually prescribed in medicine and analyze four situations to determine which would be best ethical. Although the use of placebos, whether pure (i.e., containing no active substance) or impure (i.e., containing active substances but used in a non-specific manner), is commonplace in medicine, patients are not duly informed: this practice respects neither patient autonomy nor freedom of choice. In contrast, the use of open-label placebos (i.e., prescribed to the patient in full transparency) solves this ethical problem. Importantly, informing the patient about the placebo does not seem to alter its therapeutic effect. Furthermore, the information given to the patient as part of the shared-medical decision generally does not mention the benefits that a placebo could bring to the patient in place of a pharmacologically active drug. However, scientific data on the efficacy of a placebo is available in randomized controlled trials or meta-analyses for almost all drugs. This effect is sometimes high under specific clinical conditions. We conclude that there is an ethical imperative to inform patients of the efficacy of a placebo in a clinical context where the prescription of a pharmacologically active drug is discussed. The open-label placebo option should become more systematic in medicine, particularly in psychological symptoms or conditions with a well-documented significant placebo effect. Aside from this ethical aspect, prescribing more placebos could be a way of combating overprescription, reducing inappropriate drug use and iatrogenia, and supporting the eco-responsible approach to prescribing in medicine.

Indexed as

deprescribingethicsopen-label placeboplacebopsychotropics

Identifiers

PMID42682929
PMCPMC13530445

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.